PriyaUdayKumthekarMD

Clinical Trials

• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Start of enrollment: 2009 Sep 01

  Recruiting

  Phase 3

• Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Start of enrollment: 2010 Jun 17

  Completed

  Phase 2

• Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01

  Completed

  Phase 1, Phase 2

• Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy Start of enrollment: 2013 Nov 27

  Completed

  Phase 2

• ANG1005 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2013 Oct 01

  Completed

  Phase 2

• Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01

  Terminated

  Phase 2

• ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases Start of enrollment: 2014 Apr 01

  Completed

  Phase 2

• AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Start of enrollment: 2016 Apr 01

  Completed

  Phase 1, Phase 2

• Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma Start of enrollment: 2016 Aug 01

  Recruiting

  Phase 2

• NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery Start of enrollment: 2017 May 25

  Completed

  Early Phase 1

• A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2020 Jun 08

  Terminated

  Phase 1, Phase 2

  Roles: Principal Investigator, Contact

• Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Start of enrollment: 2020 Dec 10

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator, Contact

• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers Start of enrollment: 2017 Jul 13

  Recruiting

  Phase 2

  Roles: Contact

• Join now to see all